(Q46656752)

24 December 2017

title

Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study (English)

1 reference

24 December 2017

1 reference

11

Sibylle Loibl

1 reference

24 December 2017

Gunter von Minckwitz

1

1 reference

24 December 2017

Sherko Kümmel

2

1 reference

24 December 2017

Petra Vogel

3

1 reference

24 December 2017

Claus Hanusch

4

1 reference

24 December 2017

Holger Eidtmann

5

1 reference

24 December 2017

Jörn Hilfrich

6

1 reference

24 December 2017

Bernd Gerber

7

1 reference

24 December 2017

Jens Huober

8

1 reference

24 December 2017

Serban Dan Costa

9

1 reference

24 December 2017

Christian Jackisch

10

1 reference

24 December 2017

Keyur Mehta

12

1 reference

24 December 2017

Manfred Kaufmann

13

1 reference

24 December 2017

German Breast Group

14

1 reference

24 December 2017

language of work or name

English

0 references

publication date

8 April 2008

1 reference

24 December 2017

Journal of the National Cancer Institute

published in

1 reference

24 December 2017

volume

100

1 reference

24 December 2017

issue

8

1 reference

24 December 2017

page(s)

552-562

1 reference

24 December 2017

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN089

Adjuvant docetaxel for node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN089

In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN089

Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN089

Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN089

[Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy]

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN089

Self-designing clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN089

Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN089

Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN089

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJN089

1 reference

24 December 2017

PubMed ID

18398094

1 reference

24 December 2017